OREGA Biotech (France)

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

Ivan Perrot, Henri‐Alexandre Michaud, Marc Giraudon-Paoli et al. · Cell Reports · 2019 · 404 citations · Full text

Cancer Immunosurveillance, Medicine, Immune Checkpoint Inhibitors +15

IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2

Stéphanie Cochaud, Jérôme Giustiniani, Clémence Thomas et al. · Scientific Reports · 2013 · 134 citations · Full text

Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism

Patrik Sundström, Hanna Stenstad, Veronica Langenes et al. · Cancer Immunology Research · 2016 · 72 citations · Full text

IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells

Sarah Mombelli, Stéphanie Cochaud, Yacine Merrouche et al. · Scientific Reports · 2015 · 55 citations · Full text

The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway

Emilie Laprévotte, Stéphanie Cochaud, Stanislas du Manoir et al. · Oncotarget · 2017 · 52 citations · Full text